Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
1999-04-01
2001-11-20
Carr, Deborah (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C554S126000
Reexamination Certificate
active
06319950
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a suppression of carcinoma using a high purity conjugated linoleic acid (CLA) provided by a novel synthesis of the conjugated linoleic acid (CLA). In one aspect, this invention relates to a suppression of carcinoma using a high purity conjugated linoleic acid (CLA) provided by a novel synthesis of 9-cis, 11-trans octadecadienoic acid, also known as 9(Z),11(E)-octadecadienoic acid.
2. Background
Conjugated linoleic acid (CLA) is a general term used to name positional and geometric isomers of linoleic acid.
Linoleic acid is a straight chain carboxylic acid having double bonds between the ninth and tenth carbons and between the twelfth and thirteenth carbons. Linoleic acid is 9-cis, 12-cis octadecadienoic acid [9(Z),12(Z)-octadecadienoic acid]. The numbers are counted from the carboxylic acid moiety. See Formula (1).
Conjugated linoleic acid (CLA) has two conjugated double bonds between the ninth and the twelfth carbons or between the tenth and thirteenth carbons, with possible cis and trans combinations. Conjugated double bonds means two or more double bonds which alternate in an unsaturated compound as in 1,3 butadiene. The hydrogen atoms are on the same side of the molecule in the case of cis. The hydrogen atoms are on the opposite side of the molecule in the case of trans. See Formula (2).
The free, naturally occurring conjugated linoleic acids (CLA) have been previously isolated from fried meats and described as anticarcinogens by Y. L Ha, N K. Grimm and M. W. Pariza, in Carcinogenesis, Vol. 8, No. 12, pp. 1881-1887 (1987). Since then, they have been found in some processed cheese products (Y. L. Ha, N. K. Grimm and M. W. Pariza, in J. Agric. Food Chem., Vol. 37, No. 1, pp. 75-81 (1987)).
Cook et al. in U.S. Pat. No. 5,554,646 disclose animal feeds containing CLA, or its non-toxic derivatives, e.g., such as the sodium and potassium salts of CLA, as an additive in combination with conventional animal feeds or human foods. CLA makes for leaner animal mass.
INTRODUCTION TO THE INVENTION
Conjugated linoleic acid (CLA) has a significant potency relative to other fatty acids in respect to an ability to modulate tumorigenisis. Conjugated linoleic acid (CIA) is closely related to linoleic acid but differs from linoleic acid in the position and configuration of the double bonds. Linoleic acid has a stimulatory effect on Carcinogenesis, as contrasted with the ability of conjugated linoleic acid (CLA) to inhibit tumor development. In this way, conjugated linoleic acid (CLA) has an opposite effect as contrasted with linoleic acid in treating carcinoma.
Further comparing the ability of conjugated linoleic acid (CLA) relative to other fatty acids in respect to an ability to modulate tumorigenisis, eicosapentaenoic acid and docosahexaenoic are the major components in fish oil which are responsible for tumor suppression. However, the amount of fish oil needed to suppress tumors will exceed 10% in the diet.
Adding conjugated linoleic acid (CIA) in respect to an ability to modulate tumorigenisis is contrasted with a method of reducing fat intake, nonspecific fat intake, to inhibit tumors.
Accordingly, conjugated linoleic acid (CLA) has a significant potency relative to other fatty acids in respect to an ability to modulate tumorigenisis.
The free acid forms of the CLA may be prepared by isomerizing linoleic acid. The terms “conjugated linoleic acids” and “CLA” as used herein are intended to include 9,11-octadecadienoic acid, 10,12-octadecadienoic acid, mixtures thereof, and the non-toxic salts of the acids. The non-toxic salts of the free acids may be made by reacting the free acids with a non-toxic base.
Historically, CLA was made by heating linoleic acid in the presence of a base. The term CLA (conjugated linoleic acid) refers to the prior art preparation involving alkali cooking of linoleic acid.
A conventional method of synthesizing CIA is described in Example I. However, CLA may also be prepared from linoleic acid by the action of a linoleic acid isomerase from a harmless microorganism, such as the Rumen bacterium
Butyrivibrio fibrisolvens.
Harmless microorganisms in the intestinal tracts of rats and other monogastric animals may also convert linoleic acid to CLA (S. F. Chin, J. M. Storkson, W. Liu, K. Albright and M. W. Pariza 1994, J. Nutr., 124; 694-701).
The prior art method of producing conjugated linoleic acids (CLA) can be seen in the following Example I using starting materials of linoleic acid or safflower oil.
EXAMPLE I
Synthesis of Conjugated Linoleic Acids (CLA) from Linoleic Acid/Safflower Oil
Ethylene glycol (1000 g) and 500 g potassium hydroxide (KOH) are put into a 4-neck round bottom flask (5000 ml). The flask is equipped with a mechanical stirrer, a thermometer, a reflux condenser, and a nitrogen inlet. The nitrogen to be introduced is first run through two oxygen traps.
Nitrogen is bubbled into the ethylene glycol and KOH mixture for 20 minutes, and the temperature is then raised to 180° C.
1000 g of linoleic acid, corn oil, or safflower oil is then introduced into the flask. The mixture is heated at 180° C. under an inert atmosphere for 2.5 hours.
The reaction mixture is cooled to ambient conditions, and 600 ml HCL are added to the mixture which is stirred for 15 minutes. The pH of the mixture is adjusted to pH 3. Next, 200 ml of water is added into the mixture and stirred for 5 minutes. The mixture is transferred into a 4 L separatory funnel and extracted three times with 500 ml portions of hexane.
The aqueous layer is drained, and the combined hexane solution is extracted with four 250-ml portions of 5% NaCl solution.
The hexane is washed 3 times with water. The hexane is transferred to a flask, and the moisture in the hexane is removed with anhydrous sodium sulfate (Na
2
SO
4
). The hexane is filtered through Whatman paper into a clean 1000 ml round bottom flask, and the hexane is removed under vacuum with a rotoevaporator to obtain the CLA. The CLA is stored in a dark bottle under argon at −80° C. until time of use.
The CLA obtained by the practice of the described prior art methods of preparation typically contains two or more of the 9,11-octadecadienoic acids and/or 10-12-octadecadienoic acids and active isomers thereof. After alkali treatment, the compound may be in the free acid or salt form. The CLA is heat stable and can be used as is, or it may be dried in a solvent. The CLA is readily converted into a non-toxic salt, such as the sodium or potassium salt, by reacting chemically equivalent amounts of the free acid with an alkali hydroxide at a pH of about 8 to 9.
Theoretically, eight (8) possible geometric isomers of 9,11 and 10,12-octadecadienoic acid (c9,c11; c9,t11; t9,c11; t9,t11; c10,c12; c10,t12; t10,c12; and t10,t12) would form from the isomerization of c9,c12 octadecadienoic acid. As a result of the isomerization, only four isomers (c9,c11; c9,t11; t10,c12; and c10,c12) would be expected. However, of the four isomers, c9,t11- and t10,c12-isomers are predominantly produced during the autoxidation or alkali isomerization of c9,c12-linoleic acid because of the co-planar characteristics of 5 carbon atoms around a conjugated double bond and spatial conflict of the resonance radical. The remaining two c,c-isomers are minor contributors as are the other isomers. Because of double bond shifts, more isomers are produced. Positional isomers have been found for a total of twelve isomers identified so far.
The relatively higher distribution of the t,t-isomers of 9,11- or 10,12-octadecadienoic acid apparently results from the further stabilization of c9,t11- or t10,c12-geometric isomers, which is thermodynamically preferred, during an extended processing time or long aging period. Additionally, the t,t-isomer of 9,11- or 10,12-octadecadienoic acid predominantly formed during the isomerization of linoleic acid geometrical isomers (t9,t12-, c9,t12-, and t9,c12-octadecadienoic acid) may influence the final ratio of the isomers or the final CLA content in the samples.
Carr Deborah
Glantz Douglas G.
LandOfFree
Suppression of carcinoma using high purity conjugated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Suppression of carcinoma using high purity conjugated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suppression of carcinoma using high purity conjugated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2605945